Elsewhere, Natera, Inc. (NASDAQ:NTRA), along with Quantum Leap Healthcare Collaborative, announced about publication of new ...
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently received the Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the Phase II ...
Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study Men with untreated mCRPC were randomly ...
The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because ...
We conducted an open-label, randomized study involving MSM and transgender women who were taking preexposure prophylaxis (PrEP) against human immunodeficiency virus (HIV) infection (PrEP cohort) or ...
A large trial of people with earlier stages of prostate cancer compared two types of external radiation treatments head-to-head—proton beam therapy and intensity-modulated radiation therapy, or ...
Anyone who’s read my stuff with any regularity is acutely aware of my disdain for the way many observational studies are conducted and interpreted in health and nutrition research, as well as my ...
Lake County Record-Bee on MSN
New drug may slow progression of ALS in small group of patients: Study
A new drug may slow progression of — and even reverse — symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds.
It comes on the heels of the CDC Advisory Council on Immunization Practices eliminating long-standing recommendations for hepatitis B vaccines for newborns. Health Secretary Robert F. Kennedy Jr.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback